Compare Diamondback Energy Inc (FANG) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Diamondback Energy Inc vs Novo Nordisk A/S — how do they compare? Diamondback Energy Inc trades at $190.46 (market cap $53.38B), while Novo Nordisk A/S trades at $51.46 (market cap $222.24B). The key difference: Novo Nordisk A/S is far larger — about 4.2× Diamondback Energy Inc's market cap, and Novo Nordisk A/S pays the higher dividend (3.56%). Which is the better fit depends on your goals.
| FANG | NVO | |
|---|---|---|
Market Cap | $53.38B | $222.24B |
Sector | Energy | Health |
52-Week High | $213.69 | $71.70 |
52-Week Low | $134.53 | $35.29 |
Enterprise Value | $67.11B | $241.20B |
Dividend Yield | 2.32% | 3.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Diamondback Energy (FANG) trades at $191.28, up 0.31% on the day, with a bullish technical signal and strong analyst support. Recent earnings show mixed results, beating estimates in Q1 2026 but missing in Q4 2025, while revenue growth remains robust. The company maintains solid cash flow from operations and a manageable debt-to-asset ratio of 22.26% as of 2025. A dividend of $1.10 was recently declared, with the next earnings report scheduled for August 3, 2026.
FANG presents a favorable outlook with a consensus price target of $234.50, implying 22.6% upside, supported by 90% buy ratings from analysts. Risks include volatile oil prices, geopolitical factors affecting energy markets, and declining net income margins. The stock's high P/E ratio of 193.63 warrants caution, but strong operational cash flow and institutional bullishness provide a solid foundation for growth-oriented investors.
Novo Nordisk (NVO) trades at $51.52, up 4.99% in the last session, with strong technical momentum and bullish moving averages. The company maintains robust fundamentals, including a 37.2% net income margin and consistent earnings beats in recent quarters. Recent EU approval for the Wegovy weight-loss pill (Reuters, 2026-07-15) reinforces its leadership in GLP-1 therapies, though competition is intensifying.
Outlook remains positive given solid cash flow growth and analyst support, but risks include pricing pressure from generics and slowing prescription trends. The stock's valuation at a P/E of 12.14 offers relative value in the pharma sector, with upside potential if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Diamondback Energy Inc
Diamondback Energy is an independent oil and gas producer in the United States. The company operates exclusively in the Permian Basin. At the end of 2021, the company reported net proven reserves of 1.8 billion barrels of oil equivalent. Net production averaged about 375,000 barrels per day in 2021, at a ratio of 60% oil, 20% natural gas liquids, and 20% natural gas.
Read more on FANG →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
